Advertisement

General Thoracic and Cardiovascular Surgery

, Volume 63, Issue 4, pp 201–215 | Cite as

Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014

  • Yoshihisa Kadota
  • Hirotoshi Horio
  • Takeshi Mori
  • Noriyoshi Sawabata
  • Taichiro Goto
  • Shin-ichi Yamashita
  • Takeshi Nagayasu
  • Akinori Iwasaki
Current Topics Review Article

Abstract

Thymectomy is regarded as a useful therapeutic option for myasthenia gravis (MG), though perioperative management in MG patients is largely empirical. While evidence-based medicine is limited in the perioperative management of MG patients, treatment guidelines are required as a benchmark. We selected issues faced by physicians in clinical practice in the perioperative management of extended thymectomy for MG, and examined them with a review of the literature. The present guidelines have reached the stage of consensus within the Japanese Association for Chest Surgery.

Keywords

Myasthenia gravis Perioperative management Thymectomy Myastenic crisis Consensus statement 

Notes

Acknowledgments

The authors thank the former guidelines committees of Japanese Association for Chest Surgery: Drs. Hiroaki Nomori and Masazumi Watanabe for their contribution to this work.

Conflict of interest

The authors have declared that no Conflict of interest exists.

References

  1. 1.
    Drachman DB. Medical progress—myasthenia-gravis. N Engl J Med. 1994;330(25):1797–810.PubMedGoogle Scholar
  2. 2.
    Accreditation criterion of myasthenia gravis. Nervous muscle diseases study group, Welfare Labor Ministry. http://www.nanbyou.or.jp/sikkan/049_i.htm#.Google Scholar
  3. 3.
    Jaretzki A 3rd, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23.PubMedGoogle Scholar
  4. 4.
    Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Hoch W, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–8.PubMedGoogle Scholar
  6. 6.
    Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274):2122–8.PubMedGoogle Scholar
  7. 7.
    Blalock A, et al. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg. 1939;110(4):544–61.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Sauerbruch EF. Mitteilungen aus dem Grenzgebieten der Medizin und Chirungie. 1913;25:746.Google Scholar
  9. 9.
    Schumacher E, Roth J. Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenie. Mitt Grengeb Med Chir. 1912;25:746–65.Google Scholar
  10. 10.
    Kadota Y, et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin Exp Immunol. 2000;121(1):59–68.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Leite MI, et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol. 2007;171(3):893–905.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Morgenthaler TI, et al. Thymoma. Mayo Clin Proc. 1993;68(11):1110–23.PubMedGoogle Scholar
  13. 13.
    Mygland A, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000;57(4):527–31.PubMedGoogle Scholar
  14. 14.
    Scadding GK, et al. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology. 1981;31(8):935–43.PubMedGoogle Scholar
  15. 15.
    Scarpino S, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007;149(3):504–12.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Schluep M, et al. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol. 1987;22(2):212–22.PubMedGoogle Scholar
  17. 17.
    Strobel P, et al. Selective loss of regulatory T cells in thymomas. Ann Neurol. 2004;56(6):901–4.PubMedGoogle Scholar
  18. 18.
    Lindberg C, et al. Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated. Acta Neurol Scand. 1992;86(3):323–8.PubMedGoogle Scholar
  19. 19.
    Masaoka A, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996;62(3):853–9.PubMedGoogle Scholar
  20. 20.
    Newsom-Davis J, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci. 2008;1132:344–7.PubMedGoogle Scholar
  21. 21.
    Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7–15.PubMedGoogle Scholar
  22. 22.
    Bulkley GB, et al. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg. 1997;226(3):324–34 (discussion 334-5).PubMedCentralPubMedGoogle Scholar
  23. 23.
    Mack MJ. Video-assisted thoracoscopy thymectomy for myasthenia gravis. Chest Surg Clin N Am. 2001;11(2):389–405 (xi-xii).PubMedGoogle Scholar
  24. 24.
    Sonett JR, Jaretzki A 3rd. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Ann N Y Acad Sci. 2008;1132:315–28.PubMedGoogle Scholar
  25. 25.
    Masaoka A, Nagaoka Y, Kotake Y. Distribution of thymic tissue at the anterior mediastinum. Current procedures in thymectomy. J Thorac Cardiovasc Surg. 1975;70(4):747–54.PubMedGoogle Scholar
  26. 26.
    Pompeo E, et al. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg. 2009;36(1):164–9.PubMedGoogle Scholar
  27. 27.
    Shiono H, et al. Comparison of outcomes after extended thymectomy for myasthenia gravis: bilateral thoracoscopic approach versus sternotomy. Surg Laparosc Endosc Percutan Tech. 2009;19(6):424–7.PubMedGoogle Scholar
  28. 28.
    Kondo K, Monden Y. Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg. 2005;79(1):219–24.PubMedGoogle Scholar
  29. 29.
    Christensen PB, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology. 1993;43(9):1779–83.PubMedGoogle Scholar
  30. 30.
    Compston DA, et al. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103(3):579–601.PubMedGoogle Scholar
  31. 31.
    Evoli A, et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000;48(11):1442–8.PubMedGoogle Scholar
  32. 32.
    Ishii W, et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci. 2007;14(2):110–5.PubMedGoogle Scholar
  33. 33.
    Evoli A, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord. 2001;11(2):208–16.PubMedGoogle Scholar
  34. 34.
    Nakamura H, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg. 1996;112(2):371–5.PubMedGoogle Scholar
  35. 35.
    Schumm F, et al. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48(4):332–7.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Sommer N, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62(2):156–62.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Okumura M, et al. Biological implications of thymectomy for myasthenia gravis. Surg Today. 2010;40(2):102–7.PubMedGoogle Scholar
  38. 38.
    Monden Y, et al. Effects of preoperative duration of symptoms on patients with myasthenia gravis. Ann Thorac Surg. 1984;38(3):287–91.PubMedGoogle Scholar
  39. 39.
    Nieto IP, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg. 1999;67(6):1568–71.PubMedGoogle Scholar
  40. 40.
    Uchino M, et al. Clinical analysis of 114 patients with myasthenia gravis (MG). Investigation of the actual condition of increasing aged patients with MG and efficacy of extended thymectomy. Neurol Therap. 2000;17:355–9.Google Scholar
  41. 41.
    Motomura M. Standard treatment for late-onset myasthenia gravis in Japan. Rinsho Shinkeigaku. 2011;51(8):576–82.PubMedGoogle Scholar
  42. 42.
    Perlo VP, Arnason B, Castleman B. The thymus gland in elderly patients with myasthenia gravis. Neurology. 1975;25(3):294–5.PubMedGoogle Scholar
  43. 43.
    Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology. 1990;40(12):1828–9.PubMedGoogle Scholar
  44. 44.
    Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci. 2008;1132:238–43.PubMedGoogle Scholar
  45. 45.
    Matsuzaki Y, et al. Influence of age on extended thymectomy as a treatment for myasthenia gravis. Ann Thorac Cardiovasc Surg. 1998;4(4):192–5.PubMedGoogle Scholar
  46. 46.
    Monden Y, et al. Myasthenia gravis in elderly patients. Ann Thorac Surg. 1985;39(5):433–6.PubMedGoogle Scholar
  47. 47.
    Tsuchida M, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg. 1999;67(6):1563–7.PubMedGoogle Scholar
  48. 48.
    Nagaishi A, et al. Survey on perioperative and postoperative treatment for Myasthenia Gravis patients with thymectomy. Jpn Assoc Res Thymus. 2011;30:36.Google Scholar
  49. 49.
    Rodriguez M, et al. Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13(5):504–10.PubMedGoogle Scholar
  50. 50.
    Andrews PI, et al. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44(7):1208–14.PubMedGoogle Scholar
  51. 51.
    Leite MI, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131(Pt 7):1940–52.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Leite MI, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57(3):444–8.PubMedGoogle Scholar
  53. 53.
    Hayashi A, et al. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis. J Neuroimmunol. 2007;189(1–2):163–8.PubMedGoogle Scholar
  54. 54.
    Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–22.PubMedGoogle Scholar
  55. 55.
    Engel AG, Lambert EH, Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology. 1973;23(12):1273–81.PubMedGoogle Scholar
  56. 56.
    Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol. 2003;23(2):191–8.PubMedGoogle Scholar
  57. 57.
    Skeie GO, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893–902.PubMedGoogle Scholar
  58. 58.
    Krucylak PE, Naunheim KS. Preoperative preparation and anesthetic management of patients with myasthenia gravis. Semin Thorac Cardiovasc Surg. 1999;11(1):47–53.PubMedGoogle Scholar
  59. 59.
    Inada Y. Anesthesia in uncommon diseases, Anesthesia 21 centurey. 2000. p. 4–8.Google Scholar
  60. 60.
    Okumura M et al., Thymectomy for Myasthenia Gravis. The 15th Chest Surgery Seminar, The 67th Annual Meeting of the Japanese Association for Chest Surgery 2009. p. 35–39.Google Scholar
  61. 61.
  62. 62.
    Kadota Y. et al., Perioperative treatment of myasthenia gravis., Knack & Pitfalls for the specialists in general thoracic surgery. Bunkodo, Tokyo, 2010. p. 141–145.Google Scholar
  63. 63.
    Munsat TL. Anticholinesterase abuse in myasthenia gravis. J Neurol Sci. 1984;64(1):5–10.PubMedGoogle Scholar
  64. 64.
    Diaz-Manera J, Rojas-Garcia R, Illa I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother. 2009;10(8):1329–42.PubMedGoogle Scholar
  65. 65.
    Cosi V, et al. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand. 1991;84(1):33–9.PubMedGoogle Scholar
  66. 66.
    Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291–8.PubMedGoogle Scholar
  67. 67.
    Warmolts JR, Engel WK, Whitaker JN. Alternate-dy prednisone in a patient with myasthenia gravis. Lancet. 1970;2(7684):1198–9.PubMedGoogle Scholar
  68. 68.
    Huang CS, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand. 2005;112(2):108–14.PubMedGoogle Scholar
  69. 69.
    Nagane Y, et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol. 2011;65(1):16–22.PubMedGoogle Scholar
  70. 70.
    Endo S, et al. Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis. Ann Thorac Surg. 2004;77(5):1745–50.PubMedGoogle Scholar
  71. 71.
    Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology. 1976;26(8):729–40.PubMedGoogle Scholar
  72. 72.
    Yamaguchi Y, et al. Favorable results of thymectomy combined with prednisolone alternate-day administration in myasthenia gravis. Jpn J Surg. 1987;17(1):14–20.PubMedGoogle Scholar
  73. 73.
    Hara M, et al. Evaluation of treatment for myasthenia gravis in 37 patients. The effect of pre-thymectomy corticosteroid therapy. Neurol Therap. 1994;11(1):57–65.Google Scholar
  74. 74.
    Arai H, Ito N, Hirayama K. Long-term corticosteroid therapy combined with thymectomy in generalized myasthenia gravis. Neurol Therap. 1995;12(5):437–43.Google Scholar
  75. 75.
    Bromberg MB, et al. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59–62.PubMedGoogle Scholar
  76. 76.
    Evoli A, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol. 1992;32(1):37–43.PubMedGoogle Scholar
  77. 77.
    Joint Committee of the Japanese Society for Neuroimmunology and the Japanese Society of Neurological Therapeutics, Treatment Guidelines for Myasthenia Gravis., http://www.jsnt.gr.jp/guideline/meneki.html.
  78. 78.
    Torda C, Wolff HG. Effect of blood serum from patients with myasthenia gravis on the synthesis of acetylcholine in vitro. J Clin Invest. 1944;23(5):649–56.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Torda C, Wolff HG. Effects of adrenocorticotrophic hormone on neuro-muscular function in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1949;71(3):432–5.PubMedGoogle Scholar
  80. 80.
    Brunner NG, Namba T, Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology. 1972;22(6):603–10.PubMedGoogle Scholar
  81. 81.
    Jenkins RB. Treatment of myasthenia gravis with prednisone. Lancet. 1972;1(7754):765–7.PubMedGoogle Scholar
  82. 82.
    Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974;290(2):81–4.PubMedGoogle Scholar
  83. 83.
    Saag KG. Prevention of glucocorticoid-induced osteoporosis. South Med J. 2004;97(6):555–8.PubMedGoogle Scholar
  84. 84.
    Matsuyama H, Irita K, et al. Steroid coverage: current concept. J Clin Anesth (Jpn). 2004;28(2):219–25.Google Scholar
  85. 85.
    Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia. 1998;53(11):1091–104.PubMedGoogle Scholar
  86. 86.
    Tasch MD. Corticosteroids and anesthesia. Curr Opin Anaesthesiol. 2002;15(3):377–81.PubMedGoogle Scholar
  87. 87.
    Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–40.PubMedGoogle Scholar
  88. 88.
    Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143(12):1222–6.PubMedGoogle Scholar
  89. 89.
    Yong SL, et al. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev. 2009; (4):367.Google Scholar
  90. 90.
    Arsura E, et al. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol. 1985;42(12):1149–53.PubMedGoogle Scholar
  91. 91.
    Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97(6):370–3.PubMedGoogle Scholar
  92. 92.
    Arai H, Omiyama J, HIrayama K. Methylprednisolone pulse therapy for patients with intractable generalized myasthenia gravis. Neurol Therap. 1988;5(3):265–71.Google Scholar
  93. 93.
    Tuchiyama M, Yuasa R. Intermittent methylprednisolone pulse therapy for ocular muscle myasthenia gravis. Neurol Therap. 1995;12(3):219–21.Google Scholar
  94. 94.
    Ciafaloni E, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55(3):448–50.PubMedGoogle Scholar
  95. 95.
    Evoli A, et al. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002;25(1):111–4.PubMedGoogle Scholar
  96. 96.
    Tada M, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci. 2006;247(1):17–20.PubMedGoogle Scholar
  97. 97.
    Tindall RS, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.PubMedGoogle Scholar
  98. 98.
    Tindall RS, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719–24.PubMedGoogle Scholar
  99. 99.
    Ponseti JM, et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254–63.PubMedGoogle Scholar
  100. 100.
    Nagane Y, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis–a randomized pilot study. Eur Neurol. 2005;53(3):146–50.PubMedGoogle Scholar
  101. 101.
    Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry. 2005;44(6):2030–8.PubMedGoogle Scholar
  102. 102.
    Takamori M, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology. 2004;62(10):1894–6.PubMedGoogle Scholar
  103. 103.
    Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778–83.PubMedGoogle Scholar
  104. 104.
    Munakata R, et al. The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis. Eur Neurol. 2002;48(2):115–7.PubMedGoogle Scholar
  105. 105.
    Newsom-Davis J, et al. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979;1(8114):464–8.PubMedGoogle Scholar
  106. 106.
    Matsuo H, et al. Plasmapheresis-plasma exchange therapy in myasthenia gravis, Treatments of Myasthenia gravis 2003. Neulrological Medicine. 2003;59(3):249–54.Google Scholar
  107. 107.
    Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002; (4):CD002275.Google Scholar
  108. 108.
    Gajdos P, et al. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med. 1983;12(15):939–42.PubMedGoogle Scholar
  109. 109.
    Nagayasu T, et al. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Jpn J Thorac Cardiovasc Surg. 2005;53(1):2–7.PubMedGoogle Scholar
  110. 110.
    Arsura EL, et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986;146(7):1365–8.PubMedGoogle Scholar
  111. 111.
    Elovaara I, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908.PubMedGoogle Scholar
  112. 112.
    Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–41.PubMedGoogle Scholar
  113. 113.
    Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–75.PubMedGoogle Scholar
  114. 114.
    Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis. 2008;9(3):352–5.PubMedGoogle Scholar
  115. 115.
    Huang CS, et al. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand. 2003;108(2):136–8.PubMedGoogle Scholar
  116. 116.
    O’Riordan JI, et al. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol. 1998;5(2):137–42.PubMedGoogle Scholar
  117. 117.
    Younger DS, Raksadawan N. Medical therapies in myasthenia gravis. Chest Surg Clin N Am. 2001;11(2):329–36.PubMedGoogle Scholar
  118. 118.
    Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009;102(2):97–107.PubMedGoogle Scholar
  119. 119.
    Kuks JBM, Oosterhuis HJG. Clinical presentation of myasthenia gravis. In: H.J. Kaminski HJ, editors. Neurology: myasthenia gravis and related disorders. NJ: Humana Press Inc; 2003. p. 93–114.Google Scholar
  120. 120.
    Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004;24(1):17–20.PubMedGoogle Scholar
  121. 121.
    Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24(1):75–81.PubMedGoogle Scholar
  122. 122.
    Watanabe A, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 2004;127(3):868–76.PubMedGoogle Scholar
  123. 123.
    Berrouschot J, et al. Therapy of myasthenic crisis. Crit Care Med. 1997;25(7):1228–35.PubMedGoogle Scholar
  124. 124.
    Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670–7.PubMedGoogle Scholar
  125. 125.
    Thomas CE, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253–60.PubMedGoogle Scholar
  126. 126.
    Gracey DR, et al. Postoperative respiratory care after transsternal thymectomy in myasthenia gravis. A 3-year experience in 53 patients. Chest. 1984;86(1):67–71.PubMedGoogle Scholar
  127. 127.
    Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology. 1980;53(1):26–30.PubMedGoogle Scholar
  128. 128.
    Walker MB. Case showing the effect of prostigmin on myasthenia gravis. Proc R Soc Med. 1935;28(6):759–61.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261(1–2):127–33.PubMedGoogle Scholar
  130. 130.
    Yoshida S, Yamaguchi Y, Saito Y. Prediction of postoperative respiratory failure after thymectomy combined with prednisolone alternate-day administration in myasthenia gravis. J Jpn Assoc Chest Surg. 1997;11(2):136–43.Google Scholar
  131. 131.
    Adachi M, Uehira A, Urabe T, Tanaka A, Yamauchi N, Sato T. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis patients. Masui. 1990;39(11):1484–90.PubMedGoogle Scholar
  132. 132.
    Kaneda K, Amaha K, Tanaka N, et al. A new scoring system for predicting the need for postoperative mechanical ventilation in patients with myasthenia gravis. J Jpn Soc Intensive Care Med. 1995;1:7–13.Google Scholar
  133. 133.
    Gorback MS, Moon RE, Massey JM. Extubation after transsternal thymectomy for myasthenia gravis: a prospective analysis. South Med J. 1991;84(6):701–6.PubMedGoogle Scholar
  134. 134.
    Mori T, et al. Changes in respiratory condition after thymectomy for patients with myasthenia gravis. Ann Thorac Cardiovasc Surg. 2003;9(2):93–7.PubMedGoogle Scholar
  135. 135.
    Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3(3):213–5.PubMedGoogle Scholar
  136. 136.
    Blot F, Melot C. Indications, timing, and techniques of tracheostomy in 152 French ICUs. Chest. 2005;127(4):1347–52.PubMedGoogle Scholar
  137. 137.
    Durbin CG Jr. Tracheostomy: why, when, and how? Respir Care. 2010;55(8):1056–68.PubMedGoogle Scholar
  138. 138.
    MacIntyre NR, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest. 2001;120(6 Suppl):375S–95S.PubMedGoogle Scholar
  139. 139.
    Mori T, Yoshioka M, Iwatani K, et al. Two cases of wound infection from tracheostomy after transsternal-thymectomy for myasthenia gravis. J Jpn Assoc Chest Surg. 2004;18(5):670–5.Google Scholar
  140. 140.
    Bacchetta MD, et al. Comparison of open versus bedside percutaneous dilatational tracheostomy in the cardiothoracic surgical patient: outcomes and financial analysis. Ann Thorac Surg. 2005;79(6):1879–85.PubMedGoogle Scholar
  141. 141.
    Byhahn C, et al. Early percutaneous tracheostomy after median sternotomy. J Thorac Cardiovasc Surg. 2000;120(2):329–34.PubMedGoogle Scholar
  142. 142.
    Curtis JJ, et al. Tracheostomy: a risk factor for mediastinitis after cardiac operation. Ann Thorac Surg. 2001;72(3):731–4.PubMedGoogle Scholar
  143. 143.
    Force SD, et al. Incidence of deep sternal wound infections after tracheostomy in cardiac surgery patients. Ann Thorac Surg. 2005;80(2):618–21.PubMedGoogle Scholar
  144. 144.
    Grmoljez PF, et al. Major complications of median sternotomy. Am J Surg. 1975;130(6):679–81.PubMedGoogle Scholar
  145. 145.
    Hubner N, et al. Percutaneous dilatational tracheostomy done early after cardiac surgery–outcome and incidence of mediastinitis. Thorac Cardiovasc Surg. 1998;46(2):89–92.PubMedGoogle Scholar
  146. 146.
    Patel A, Swan P, Dunning J. Does a percutaneous tracheostomy have a lower incidence of complications compared to an open surgical technique? Interact CardioVasc Thorac Surg. 2005;4(6):563–8.PubMedGoogle Scholar
  147. 147.
    Stamenkovic SA, et al. Is early tracheostomy safe in cardiac patients with median sternotomy incisions? Ann Thorac Surg. 2000;69(4):1152–4.PubMedGoogle Scholar
  148. 148.
    Wagner F, et al. Percutaneous dilatational tracheostomy: results and long-term outcome of critically ill patients following cardiac surgery. Thorac Cardiovasc Surg. 1998;46(6):352–6.PubMedGoogle Scholar
  149. 149.
    Agarwal R, Reddy C, Gupta D. Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: case report and review of literature. Emerg Med J. 2006;23(1):e6.PubMedCentralPubMedGoogle Scholar
  150. 150.
    Seneviratne J, et al. Noninvasive ventilation in myasthenic crisis. Arch Neurol. 2008;65(1):54–8.PubMedGoogle Scholar
  151. 151.
    Seneviratne J, et al. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65(7):929–33.PubMedGoogle Scholar
  152. 152.
    Pascuzzi R. Myasthenia Gravis Foundation of America. Medications and myasthenia gravis. Available at: http://www.myasthenia.org/docs/MGFA_MedicationsandMG.pdf.
  153. 153.
    McQuillen MP, Canter HE, O’Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol. 1968;18:402–15.PubMedGoogle Scholar
  154. 154.
    Abe S, Takeuchi C, Kaneko T, Maeda M, Saitoh Y, Hikawa Y, Yasuda K. Propofol anesthesia combined with thoracic epidural anesthesia for thymectomy formyasthenia gravis–a report of eleven cases. Masui. 2001;50(11):1217–20.PubMedGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2015

Authors and Affiliations

  • Yoshihisa Kadota
    • 1
    • 2
  • Hirotoshi Horio
    • 1
    • 3
  • Takeshi Mori
    • 1
    • 4
  • Noriyoshi Sawabata
    • 1
    • 5
  • Taichiro Goto
    • 1
    • 6
  • Shin-ichi Yamashita
    • 1
    • 7
  • Takeshi Nagayasu
    • 1
    • 8
  • Akinori Iwasaki
    • 1
    • 7
  1. 1.Guidelines Committees of Japanese Association for Chest SurgeryKyotoJapan
  2. 2.Department of General Thoracic SurgeryOsaka Prefectural Medical Center for Respiratory and Allergic DiseasesOsakaJapan
  3. 3.Department of General Thoracic SurgeryTokyo Metropolitan Cancer and Infectious diseases Center Komagome HospitalTokyoJapan
  4. 4.Department of Thoracic SurgeryKumamoto University HospitalKumamotoJapan
  5. 5.Department of General Thoracic SurgeryOsaka University Graduate School of MedicineOsakaJapan
  6. 6.Department of General Thoracic SurgeryKeio University School of MedicineTokyoJapan
  7. 7.Department of General Thoracic, Breast and Pediatric SurgeryFukuoka University School of MedicineFukuokaJapan
  8. 8.Department of Surgical oncologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan

Personalised recommendations